GlassScriptPhysician profile
Danielle Schillen
NPI 1629546320
$1,964.60
in general payments reported to CMS, 2019-2025
23 companies · $40.38 in 2025
The $40.38 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $249 · 2022: $729 · 2023: $675 · 2024: $270 · 2025: $40.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $985.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $361.07 | 2021-2023 | Lumakras, Vectibix, Xgeva |
| Astrazeneca Pharmaceuticals LP | $201.73 | 2021-2023 | Imfinzi |
| Daiichi Sankyo INC. | $180.77 | 2021-2023 | Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $158.10 | 2021-2024 | |
| Taiho Oncology, INC. | $134.32 | 2022-2024 | |
| Abbvie INC. | $132.92 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $128.48 | 2022-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $117.73 | 2021-2024 | Alunbrig, Fruzaqla |
| Emd Serono, INC. | $76.51 | 2022-2023 | Tepmetko |
| Mirati Therapeutics, INC. | $68.77 | 2023-2024 | Krazati |
| Eisai INC. | $60.62 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $58.93 | 2021-2023 | Keytruda |
| Blueprint Medicines Corporation | $42.78 | 2022 | |
| G1 Therapeutics, INC. | $37.13 | 2023 | Cosela |
| Novartis Pharmaceuticals Corporation | $34.55 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $33.14 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $29.42 | 2021-2022 | |
| Cumberland Pharmaceuticals, INC. | $28.31 | 2024 | Sancuso |
| Janssen Scientific Affairs, LLC | $17.82 | 2024 | Erleada |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.00 | 2023 | Gilotrif |
| Ipsen Biopharmaceuticals, INC | $15.18 | 2023 | Somatuline Depot, Onivyde |
| Pfizer INC. | $15.00 | 2022 | |
| Foundation Medicine, INC. | $14.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Schillen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.